contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-pharma-receives-first-purchase-order-for-new-scalp-serum

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Coegin Pharma

Coegin Pharma AB ("Coegin" or the "Company") today announces that it has received its first limited purchase order for the Company's newly introduced high-performance cosmetic scalp serum within...

<div class="bequoted-body">Coegin Pharma AB ("Coegin" or the "Company") today announces that it has received its first limited purchase order for the Company's newly introduced high-performance cosmetic scalp serum within the Follicopeptide® portfolio. The order has been placed by Gents, an existing commercial partner of Coegin Pharma, ahead of the planned market launch.The order represents an early commercial step in Coegin's strategy to expand the Follicopeptide portfolio with additional science-based products that broaden the offering and increase market reach.As previously communicated, the scalp serum is designed to function both as a high-performance stand-alone cosmetic hair product and as an integrated part of the Follicopeptide portfolio. The formulation helps optimise the scalp environment while enhancing the overall user experience of Follicopeptide® Gel Serum.Production is fully outsourced to an established cosmetic manufacturing partner in Denmark, enabling rapid and scalable market introduction while allowing Coegin to maintain full operational focus on scaling in-house production of Follicopeptide® Gel Serum.&nbsp;Jens Eriksson, CEO of Coegin Pharma, comments: "Receiving the first purchase order already ahead of launch confirms strong partner interest as we expand the Follicopeptide portfolio. A broader product ecosystem strengthens our commercial offering and supports scalable growth with our partners."Jenny Rydhström, CEO of GENTS, comments: "We see strong potential in expanding our hairloss product range with Power Instant Hair Thickening Gel, which will be the commercial product name when it reaches our shelves at consumer level. It fits well within our premium grooming portfolio, and we look forward to introducing it to our customers."The order represents a further step in Coegin Pharma's transition toward a commercially driven innovation company within hair and skin.For further information, please contact: Jens Eriksson, CEO, Coegin Pharma AB Email: <a href="mailto:je@coeginpharma.com">je@coeginpharma.com</a>About Coegin Pharma Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology. Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.More information - including subscription to company updates and links to social media - is available at <a href="https://www.coeginpharma.com/">coeginpharma.com</a>&nbsp;</div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/83f633f6-7ba3-4630-8dce-f3b1e62d22b3/260304-Pressrelease.pdf">260304-Pressrelease.pdf</a> </div>